- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2007-003913-15 | Sponsor Protocol Number: ANTRAG01 | Start Date: | ||||||
Sponsor Name: Medical University Innsbruck | ||||||||
Full Title: Wirkung von Oxcarbazepin (Trileptal) auf den Kortikosteroid-Metabolismus - Pilotstudie | ||||||||
Medical condition: Oxcarbazepin, a widely-used antiepileptic treatment is evaluated with respect to Cortisol-degradation. Young adults and adults with oxcarbazepine monotherapy since at least 6 months and temporal lo... | ||||||||
|
||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |||||||
Trial protocol: AT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022785-27 | Sponsor Protocol Number: Q4882g | Start Date: | |||||||||||
Sponsor Name: Genentech, Inc. | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO Evaluate the efficacy, RESPONSE DURATION and safety OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDI... | |||||||||||||
Medical condition: CHRONIC IDIOPATHIC URTICARIA (CIU) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Completed) DK (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004806-14 | Sponsor Protocol Number: TKS-2014-001 | Start Date: | |||||||||||
Sponsor Name: Therakos, Inc. | |||||||||||||
Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ... | |||||||||||||
Medical condition: Acute graft-versus-host disease (aGvHD) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004878-99 | Sponsor Protocol Number: INCB84344-102 | Start Date: | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name: Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||||||||||||
Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) FR (Ongoing) ES (Ongoing) DE (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006597-23 | Sponsor Protocol Number: UX143-CL301 | Start Date: | |||||||||||
Sponsor Name: Ultragenyx Pharmaceutical Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta. | |||||||||||||
Medical condition: Osteogenesis imperfecta (OI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DK (Prematurely Ended) DE (Ongoing) IT (Ongoing) PL (Ongoing) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004851-22 | Sponsor Protocol Number: B7451015 | Start Date: | |||||||||||
Sponsor Name: Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001, U.S.A. | |||||||||||||
Full Title: A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with m... | |||||||||||||
Medical condition: Moderate to severe atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) HU (Trial now transitioned) PL (Ongoing) NL (Ongoing) BG (Ongoing) BE (Ongoing) LV (Ongoing) ES (Ongoing) SK (Completed) FR (Completed) AT (Completed) SE (Prematurely Ended) IT (Ongoing) FI (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004828-11 | Sponsor Protocol Number: RECHMPL18_0038_prom_7574 | Start Date: | ||||||
Sponsor Name: University Hospital of Montpellier | ||||||||
Full Title: Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III study | ||||||||
Medical condition: adult and adolescent patients with univentricular heart diseases and pulmonary arterial pressure | ||||||||
|
||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||
Trial protocol: FR (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003220-78 | Sponsor Protocol Number: I8B-MC-ITSA | Start Date: | |||||||||||
Sponsor Name: Eli Lilly and Company | |||||||||||||
Full Title: A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date: | ||||||||||||||||||||||||||
Sponsor Name: Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006907-35 | Sponsor Protocol Number: SP915 | Start Date: | |||||||||||
Sponsor Name: Schwarz Biosciences GmbH | |||||||||||||
Full Title: Long-term extension of RECOVER A MULTICENTER, MULTINATIONAL, PHASE 3B, OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE LONG-TERM EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON MOTOR FUNCTI... | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Completed) ES (Completed) HU (Completed) IT (Completed) GB (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |